发明名称 CONTROLLED RELEASE FORMULATION OF DIVALPROEX SODIUM
摘要 <p>A controlled release tablet formulation which permits once daily dosing in the treatment of epilepsy comprises from about 50 weight percent to about 55 weight percent of an active ingredient selected from the group consisting of valproic acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, and valpromide; from about 20 weight percent to about 40 weight percent hydroxypropyl methylcellulose; from about 5 weight percent to about 15 weight percent lactose, from about 4 weight percent to about 6 weight percent microcrystalline cellulose, and from about 1 weight percent to about 5 weight percent silicon dioxide having an average particle size ranging between about 1 micron and about 10 microns; all weight percentages based upon the total weight of the tablet dosage form. Also disclosed are pre-tableting granular formulations, methods of making the granular formulations and tablets, and a method of treating epilepsy employing the controlled release tablet formulations of the invention.</p>
申请公布号 SI20624(A) 申请公布日期 2002.02.28
申请号 SI19990020100 申请日期 1999.12.09
申请人 ABBOTT LABORATORIES 发明人 QUI YIHONG;POSKA RICHARD;CHESKIN HOWARD;BOLLINGER J.;ENGH KEVIN
分类号 A61K9/26;A61K9/20;A61K9/22;A61K31/16;A61K31/19;A61K31/23;A61K47/02;A61K47/26;A61K47/38;A61P25/08;(IPC1-7):A61K9/22;A61K9/16 主分类号 A61K9/26
代理机构 代理人
主权项
地址